Program details
-
SS1 Sponsored session 1 Sponsored by Dong-A ST
What is the most appropriate option as a 3rd line therapy?
Chair(s): Sung Hee Ihm
Thursday 19 October, 14:30~15:30
Room 1 (3F) -
-
SS1-1
Sung Hoon Yu Hanyang University, Korea - Early treatment of T2DM patients considering cardiorenal function
-
SS1-2
Mi Kyung Kim Keimyung University, Korea - What's new in drug treatment of diabetes
-
-
SS2 Sponsored session 2 Sponsored by Chongkundang
The advantages of combination therapy with oral antidiabetic agents
Chair(s): Jin Ook Chung
Thursday 19 October, 14:30~15:30
Room 3 (3F) -
-
SS2-1
Dughyun Choi Soonchunhyang University, Korea - Expanding the option of SGLT2 inhibitor and DPP4 inhibitor
-
SS2-2
Da Young Lee Korea University, Korea - The effects of TZD and combination therapy with DPP4i
-
-
SS3 Sponsored session 3 Sponsored by AstraZeneca
What options are available to patients with type 2 diabetes for intensified treatment?
Chair(s): Chul-Hee Kim
Thursday 19 October, 14:30~15:30
Room 4 (2F) -
-
SS3-1
Jae-Han Jeon Kyungpook National University, Korea - Holistic approach of T2D management - Cardiorenal outcome of Forxiga
-
SS3-2
Soo Heon Kwak Seoul National University, Korea - Promising approach for the management of T2DM with the combination of DPP4 inhibitors and SGLT2 inhibitors
-
-
SS4 Sponsored session 4 Sponsored by Daewoong Pharmaceutical
The meaning of glucose control today: time for a paradigm shift
Chair(s): Hyoungwoo Lee
Friday 20 October, 13:00~14:00
Room 1 (3F) -
-
SS4-1
Ramzi A. Ajjan University of Leeds, UK - Use of continuous glucose monitoring in insulin-treated patients with type 2 diabetes
-
SS4-2
Jong Chul Won Inje University, Korea - The SEOUL algorithm for managing type 2 diabetes: the PDF Study
-
-
SS5 Sponsored session 5 Sponsored by BI-LLY
The new mainstream in treatment of T2D patients with CRM benefits
Chair(s): Ie Byung Park
Friday 20 October, 13:00~14:00
Room 2 (3F) -
-
SS5-1
Jae Hyun Bae Korea University, Korea - Treating T2D patients with empagliflozin, considering heart failure
-
SS5-2
Mi Hae Seo Soonchunhyang University, Korea - Importance of early intervention for CRM
-
-
SS6 Sponsored session 6 Sponsored by Novo Nordisk
What are the new GLP-1RA benefits in T2D seen in clinical practice
Chair(s): Hyun Shik Son
Friday 20 October, 13:00~14:00
Room 3 (3F) -
-
SS6-1
Michael A Nauck St. Josef Hospital, Ruhr University Bochum, Germany - Why GLP-1 therapy is important from pathophysiological perspective of T2D
-
SS6-2
Nam Hoon Kim Korea University, Korea - How to integrate GLP-1RA into clinical practice
-
Korean Diabetes Association-
- (04146) 101-2104, Lotte Castle President, 109 Mapo-gu, Seoul, Korea
- Tel: +82-2-714-9064 | E-mail: diabetes@kams.or.kr
- Business Registration Number: 106-82-31108 | Name of Representative: Kyu-Chang Won
- Congress Secretariat (Planbear)
-
- #1101, 220, Gonghang-daero, Gangseo-gu, Seoul(07806), Republic of Korea
- Tel: +82-2-6734-1011/1012/1013 E-mail: icdm@diabetes.or.kr
copyright© By Korean Diabetes Association.
All rights reserved.
Businuess Registration Number: 106-82-31108
Name of Representative : Kyu-Chang Won
